Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is low-grade fibromyxoid sarcoma?
Low-grade fibromyxoid sarcoma (LGFMS) is a rare cancer of the soft tissues — the muscle, fat, and connective tissue beneath the skin. It usually shows up as a slowly enlarging, painless lump deep in the thigh, trunk, shoulder, or arm, often in young and middle-aged adults. Its name captures its deceptive nature: 'low-grade' because the cells look bland and inactive, 'fibromyxoid' because of the mix of fibrous and gel-like (myxoid) tissue. The catch is that despite this innocent appearance, LGFMS can come back at the original site or spread to the lungs years — even a decade or more — after it was first removed. Nearly all cases carry a characteristic gene fusion, most often FUS-CREB3L2, which pathologists can test for to confirm the diagnosis and tell it apart from truly benign lumps.
The main types
Doctors group low-grade fibromyxoid sarcoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Classic low-grade fibromyxoid sarcoma | The usual form, with alternating fibrous and myxoid zones and the FUS-CREB3L2 (or less often FUS-CREB3L1) gene fusion. |
| Hyalinizing spindle-cell variant | A subtype with distinctive collagen 'rosettes'; behaves like classic LGFMS and shares the same gene fusion. |
Staging, in plain terms
LGFMS is staged like other soft-tissue sarcomas, using tumor size and depth (T), lymph node involvement (N, rare), distant spread (M), and grade. By definition it is low-grade, which usually predicts slow behavior — but LGFMS is the exception that proves the rule, because even low-grade tumors can recur or spread late, so follow-up is long regardless of stage.
| Soft-tissue sarcoma TNM + grade | What it generally means |
|---|---|
| Localized | The tumor is confined to its original soft-tissue site. Wide surgical removal offers the best chance of cure. |
| Locally recurrent | The tumor has grown back where it started, sometimes years later. Re-excision, sometimes with radiation, is used to regain control. |
| Metastatic (usually lung) | The cancer has spread, most often to the lungs and sometimes long after the original surgery. Treatment focuses on removing or controlling the spread. |
The standard of care
Low-Grade Fibromyxoid Sarcoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Wide surgical removal (the cornerstone)
Taking out the tumor with a clear rim of healthy tissue (an R0 resection) gives the best local control and the lowest chance of return. Clean margins matter more here than almost any other treatment.
Radiation for difficult margins
Radiation is not routine, but it is added when the tumor sits where wide margins are impossible, when margins come back positive or close, or for recurrent disease — to lower the risk of the cancer growing back.
Chemotherapy — limited benefit
Standard chemotherapy works poorly against LGFMS and is rarely used, reserved mainly for widespread disease within a clinical trial.
Long-term surveillance
Because LGFMS can recur or reach the lungs a decade or more later, patients need years of follow-up imaging — including periodic chest scans — rather than being discharged after a few clear years.
How radiation treatment works
Radiation damages the DNA inside tumor cells so they can no longer divide, and it is especially useful for killing microscopic cells left behind at the edges of a surgical site. In low-grade fibromyxoid sarcoma, surgery is the main cure, but radiation steps in when the team cannot achieve a wide healthy margin — for example, a tumor wrapped around important structures — or when the cancer recurs. For an isolated lung spread, focused SBRT can eliminate the spot with just a few treatments. Radiation is painless, given as a series of short daily sessions, and leaves no radioactivity behind.
The main ways radiation is delivered for low-grade fibromyxoid sarcoma:
External-beam radiation (IMRT/IGRT)
Image-guided, intensity-modulated beams treat the tumor bed before or after surgery when margins are a concern, shaping the dose to cover at-risk tissue while sparing nearby skin, bone, and joints.
Stereotactic body radiation (SBRT)
Delivers a few precise, high doses to an isolated lung metastasis or a small recurrence, controlling it without major surgery.
Proton beam therapy
Protons stop after the target, useful for tumors near the spine or other sensitive structures, or to limit dose in younger patients.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Pooled analysis of 773 LGFMS cases: A large systematic review found that wide (R0) surgical resection gave the best recurrence-free survival, while chemotherapy and radiation added little overall — but documented 19% local recurrence and 21% metastasis, underscoring the need for long follow-up.[1]
Cancers 2026 (MDPI 18(3):364)
Clinical significance of the FUS-CREB3L2 fusion: Research confirmed that the FUS-CREB3L2 translocation is present in the large majority of cases and is a reliable diagnostic marker, helping distinguish LGFMS from benign lumps and predicting its capacity for late spread.[2]
PMC3063187
Outcomes and chemotherapy efficacy: An outcomes study reaffirmed surgery as the mainstay and the limited role of chemotherapy, while highlighting the propensity for late lung metastases that mandates extended chest surveillance.[3]
In Vivo 34(1):239 (iiarjournals)
Common questions
If it's low-grade, why do I need long-term follow-up? Low-grade fibromyxoid sarcoma is unusual: it looks calm under the microscope but can return or spread to the lungs many years — sometimes more than a decade — after surgery. That is why your team keeps watching with periodic imaging rather than discharging you after a couple of clear years.
Do I need radiation or chemotherapy? Most patients are cured by wide surgical removal alone. Radiation is added mainly when clean margins aren't possible or the tumor recurs. Chemotherapy works poorly against this cancer and is rarely used.
What does the gene-fusion test tell me? Nearly all of these tumors carry a FUS-CREB3L2 gene fusion. Finding it confirms the diagnosis and separates LGFMS from harmless lumps it can resemble — which matters because this 'harmless-looking' tumor needs proper surgery and follow-up.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.